SABRINA SANDOVAL: Open Payments
NPI 1538370721 · LONG BEACH, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,352 in 102 payments from 12 companies in 2025. Trend: 2023 $1,861 · 2024 $1,648 · 2025 $2,352
Food & beverage: $2,352
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 23 | $513 |
| Janssen Pharmaceuticals, Inc | 14 | $383 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $320 |
| Vanda Pharmaceuticals Inc. | 10 | $286 |
| Otsuka America Pharmaceutical, Inc. | 11 | $227 |
| Bausch Health US, LLC | 10 | $192 |
| Lundbeck LLC | 9 | $189 |
| Axsome Therapeutics, Inc. | 4 | $115 |
| Alkermes, Inc. | 3 | $77 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
Products named: VRAYLAR, SPRAVATO, REXULTI, CAPLYTA, FANAPT, APLENZIN, Auvelity, ARISTADA.
Industry payments across CA — which companies pay providers there.
